Poseida secures $110M for for gene therapies

Biopharmaceutical startup Poseida Therapeutics announced the closing of a $110 million Series D round led by Fidelity Management and Research.

The San Diego-based company is developing a proprietary gene engineering platform technology to create cell and gene therapeutics for cancer and genetic diseases.

More News :

With live conferences and large gatherings mostly on hold amid the COVID-19 pandemic, virtual events companies are generating heightened attention from investors, along with bigger checks. The latest to secure a sizable round is Hopin, a London-based provider of a virtual events platform that just closed on $40 million in a Series A round led by IVP.

Connect Ventures, a London-based VC firm focused on seed-stage investments, has announced a new $80 million (£65 million) fund to support product-led founders across Europe.

New York-based Doorkee, a startup offering a digital platform to incentivize tenants to give vacancy notice and assist in virtual showings, has raised $5.7 million in seed funding from Simon Baron Development, a large landlord, along with early-stage VC firms Corigin Ventures and Alpha Edison.